A genetically engineered herpes virus can halt the progression of skin cancer by killing cancer cells and sparking the immune system into action against tumours, a landmark clinical trial has shown.
It is the first time that a Phase III trial of viral immunotherapy has definitively shown benefit for patients with cancer.
The trial was led in the UK by researchers at The Institute of Cancer Research, London, and The Royal Marsden NHS Foundation Trust, and involved 64 research centres worldwide, including the University of Oxford.
Researchers randomised 436 patients with aggressive, inoperable malignant melanoma to receive either an injection of the viral therapy, called Talimogene Laherparepvec, or a control immunotherapy.
Some 16.3% of the group given Talimogene Laherparepvec – known as T-VEC – showed a durable treatment response of more than six months, compared with 2.1% given the control treatment.
Some patients had a response extending past three years, a mark oncologists often use as a proxy for cure in immunotherapy.
Importantly, responses to treatment were most pronounced in patients with less advanced cancers (stage IIIB, IIIC, IVM1a) and those who had yet to receive any treatment – underlining the potential benefits of T-VEC as a first-line treatment for metastatic melanoma which cannot be surgically removed.
Patients with stage III and early stage IV melanoma treated with T-VEC – a total of 163 people – lived an average of 41 months. This compared with an average survival of 21.5 months in the 66 earlier-stage patients who received the control immunotherapy.
The trial was funded by the manufacturer of T-VEC, Amgen, and is published in the Journal of Clinical Oncology.
T-VEC is a modified form of herpes simplex virus type-1 which multiplies inside cancer cells and bursts them from within. It has been genetically engineered to produce a molecule called GM-CSF, which stimulates the immune system to attack and destroy the tumour.
T-VEC is one of a new wave of virus-based drugs to show benefits in cancer trials, and is now the first to do so in a major randomised, controlled Phase III trial.
The virus has been modified to remove two key genes, called ICP34.5 and ICP47, so that it can’t replicate within healthy cells. Normal cells detect and destroy T-VEC before it can cause damage – but it replicates easily in cancer cells because their infection defences are compromised by genetic errors.
UK trial leader Professor Kevin Harrington, Professor of Biological Cancer Therapies at the ICR and Honorary Consultant at The Royal Marsden, said: “There is increasing excitement over the use of viral treatments like T-VEC for cancer, because they can launch a two-pronged attack on tumours – both killing cancer cells directly and marshalling the immune system against them. And because viral treatment can target cancer cells specifically, it tends to have fewer side-effects than traditional chemotherapy or some of the other new immunotherapies.
“Our study showed that T-VEC can deliver a significant, durable benefit for people with melanoma. It is encouraging that the treatment had such a clear benefit for patients with less advanced cancers – ongoing studies are evaluating if it can become a first-line treatment for more aggressive melanomas and advanced disease.”
Read more: World first as viral immunotherapy for skin cancer shows patient benefit in Phase III trial
The Latest on: Viral immunotherapy
via Google News
The Latest on: Viral immunotherapy
- Immunotherapy to shrink treatment-resistant cancer tumorson June 29, 2022 at 7:14 am
Advancements in cancer research and treatment have resulted in great improvements in survival rates—today, there are almost 17 million people in the United States alone who have survived their ...
- Oncology immunotherapy developer Genelux files for proposed $30M IPOon June 27, 2022 at 4:26 pm
Cancer drug developer Genelux Corp. has filed to raise up to $30M through an initial public offering. The company didn’t dis ...
- Novel Combination Therapy Shows Promise against Resistant Cancer in Miceon June 27, 2022 at 5:00 am
New research in animal models by scientists at Thomas Jefferson University demonstrates that using viral and bacterial vaccine approaches together is safe and effective at fighting the ...
- Cancer Immunotherapy Month: Greater Understanding of Immune System Leads to Advanced Targeted Treatmentson June 23, 2022 at 11:00 am
David L. Bartlett, MD, discussed the adoption of key immunotherapies and how exploration of the tumor microenvironment and immune environment is opening new approaches to treatment in an interview ...
- Oncorus Appoints Douglas Fambrough to Board of Directorson June 23, 2022 at 4:50 am
Designed to deliver next-generation viral immunotherapy impact, our HSV Platform improves upon key characteristics of this therapeutic class to enhance systemic activity. Our lead HSV program ...
- Oncorus Appoints Douglas Fambrough to Board of Directorson June 23, 2022 at 4:13 am
(Nasdaq: ONCR), a viral immunotherapies company focused on driving innovation to transform outcomes for cancer patients, today announced the appointment of Douglas M. Fambrough, III, Ph.D. to its ...
- Cancer patients receiving immunotherapy: No evidence of increased risk for severe immune complication after COVID-19 vaccinationon June 22, 2022 at 5:00 pm
Does COVID-19 vaccination increase the risk of cancer patients undergoing therapy with immune checkpoint inhibitors to suffer a dangerous immune complication known as a "cytokine release syndrome"? A ...
- Neoantigens' Role in Immunotherapyon June 21, 2022 at 9:31 am
Other sources of neoantigens include viral infection ... Neoantigens have become a crucial target of potential immunotherapy approaches to cancer treatment and diagnosis. Both immune checkpoint ...
- 10 Years of Immunotherapy: Advances, Innovations, and Better Patient Outcomeson June 19, 2022 at 10:00 am
The last decade of immunotherapy progress was based on decades of prior research, including other forms of immunotherapy.
via Bing News